Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18.
INSM has a 100% “Buy” opinion from Barchart with impressive recent gains.
Revenue is projected to grow nearly 29% this year and 126% next year, with earnings growth expected to accelerate in 2026.
Wall Street analysts are mostly bullish, but there is a wide range of price targets on INSM here.
Valued at $26.9 billion, Insmed (INSM) is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations. The group is patients with non-tuberculous lung infections. The second is cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, an inhaled treatment for pulmonary arterial hypertension.
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. INSM checks those boxes. Since the Trend Seeker signaled a buy on June 3, the stock gained 74.15%.
INSM Price vs. Daily Moving Averages:
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
Insmed shares hit a new 52-week high on Aug. 18, touching $130.13 in intraday trading.
Insmed has a Weighted Alpha of +67.81.
INSM has an 100% “Buy” opinion from Barchart.
The stock gained 64.02% over the past year.
INSM has its Trend Seeker “Buy” signal intact.
Insmed is trading above its 20-, 50-, and 100-day moving averages.
The stock made 15 new highs and gained 24.09% in the last month.
Relative Strength Index (RSI) is at 83.71%.
There’s a technical support level around $126.22.
Story Continues
